Literature DB >> 11123008

Clinical trials for the treatment of systemic sclerosis/scleroderma.

J Varga1, I Ponor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 11123008     DOI： 10.1007/s11926-999-0018-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  5 in total

1.  Plasmapheresis and immunosuppressive drug therapy in scleroderma.

Authors:  P C Dau; M B Kahaleh; R W Sagebiel
Journal:  Arthritis Rheum       Date:  1981-09

2.  Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.

Authors:  R M Silver; J H Warrick; M B Kinsella; L S Staudt; M H Baumann; C Strange
Journal:  J Rheumatol       Date:  1993-05       Impact factor: 4.666

3.  Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study.

Authors:  V D Steen; J K Lanz; C Conte; G R Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1994-09

4.  Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis.

Authors:  A Akesson; F A Wollheim; H Thysell; T Gustafson; L Forsberg; O Pahlm; P Wollmer; B Akesson
Journal:  Scand J Rheumatol       Date:  1988       Impact factor: 3.641

5.  A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.

Authors:  G Várai; L Earle; S A Jimenez; R M Steiner; J Varga
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.